Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF 100 Price-to-Tangible-Book is 11.76 as of Sep. 15, 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.20 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 839 Drug Manufacturers companies, BioGaia AB ranks worse than 91.54% on this metric.
As of today (2026-09-15), BioGaia AB's share price is $11.55. BioGaia AB's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $0.98. Hence, BioGaia AB's Price to Tangible Book Ratio of today is 11.76.
The historical rank and industry rank for BioGaia AB's Price-to-Tangible-Book or its related term are showing as below:
BGLAF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.75 Med: 9.91 Max: 20.56
Current: 11.55
During the past 13 years, BioGaia AB's highest Price to Tangible Book Ratio was 20.56. The lowest was 4.75. And the median was 9.91.
BGLAF's Price-to-Tangible-Book is ranked worse than 91.54% of 839
companies
in the Drug Manufacturers industry
Industry Median: 2.26
vs BGLAF: 11.55
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
BioGaia AB Price-to-Tangible-Book Related Terms
BioGaia AB Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
BioGaia AB (BGLAF) has a Price-to-Tangible-Book of 11.76 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on BioGaia AB and its competitors. According to the industry distribution chart, BioGaia AB ranks #768 out of 839 companies in the Drug Manufacturers industry, placing it in the top 91.5%.
Is BioGaia AB's Price-to-Tangible-Book too high?
BioGaia AB's current Price-to-Tangible-Book is 11.76. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.26. BioGaia AB's value of 11.76 is 420.4% above this industry median. Based on the distribution chart, BioGaia AB ranks #768 out of 839 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Price-to-Tangible-Book compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #768 out of 839 companies for Price-to-Tangible-Book. This places BioGaia AB in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.26. BioGaia AB's value of 11.76 is 420.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.26, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Price-to-Tangible-Book of 11.76 is 420.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Price-to-Tangible-Book is 11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.20, compared to a current price of $11.55 — trading 12.5% below its estimated fair value. The current Price-to-Tangible-Book is 11.76 and 420.4% above the Drug Manufacturers industry median of 2.26. BioGaia AB's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Price-to-Tangible-Book is 11.76 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $11.55 is trading 12.5% below its estimated GF Value™ of $13.20.
GuruFocus considers BioGaia AB to be Modestly Undervalued.
Key valuation signals for BGLAF:
Price-to-Tangible-Book: 11.76
GF Value™: $13.20 vs. price of $11.55 (12.5% below fair value)
Industry Position: 420.4% above the Drug Manufacturers median (#768 of 839)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
